Wiley Bros. Aintree Capital, LLC Biogen Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $12.5 Billion
- Q2 2025
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 2,859 shares of BIIB stock, worth $441,057. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,859
Previous 1,783
60.35%
Holding current value
$441,057
Previous $243,000
47.74%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding BIIB
# of Institutions
1,039Shares Held
132MCall Options Held
2.84MPut Options Held
2.54M-
Vanguard Group Inc Valley Forge, PA17.3MShares$2.67 Billion0.04% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$2.44 Billion1.62% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.24 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.47MShares$1.15 Billion0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.8MShares$740 Million0.11% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $22.2B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...